Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 401–500 of 1,004
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism
Nicholson, M. C., Goubran, H. A., Chan, N., & Siegal, D. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100970 · Cited by 22
“No thrombotic events were detected, and no deaths were attributable to thrombosis in those who received BNT162b2 [23].”
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
Tian, M., Dong, B., Li, W., Wang, L., & Yu, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101339 · Cited by 22
Liu, C., Tsang, T. K., Sullivan, S. G., Cowling, B. J., & Yang, B. (2025) · Nature Communications · doi:10.1038/s41467-025-60024-9 · Cited by 22
Gralnek, I. M., Hassan, C., Ebigbo, A., Fuchs, A., Beilenhoff, U., Antonelli, G., Bisschops, R., Arvanitakis, M., Bhandari, P., Bretthauer, M., et al. (2021) · Endoscopy · doi:10.1055/a-1700-4897 · Cited by 24
“Full vaccination has been shown to substantially reduce severe COVID-19 manifestations, intensive care unit need, and death [4, 34].”
BackgroundHollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Schaffrinski, M., Zachmann, K., Schmitz, Ä., et al. (2022) · Allergy · doi:10.1111/all.15247 · Cited by 21
Shao, Y., Wu, Y., Feng, Y., Xu, W., Xiong, F., & Zhang, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0913-y · Cited by 23
Islam, M. R. (2022) · Health Science Reports · doi:10.1002/hsr2.545 · Cited by 21
Hewins, B., Rahman, M., Bermejo-Martín, J. F., Kelvin, A. A., Richardson, C. D., Rubino, S., Kumar, A., Ndishimye, P., Ostadgavahi, A. T., Mahmud-Al-Rafat, A., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.849936 · Cited by 23
“3% effective against COVID-19 through 6 months of follow-up and a further 96·7% effective against severe disease (13).”
BackgroundNew-Onset Acute Kidney Disease Post COVID-19 Vaccination
Li, Y., Rao, M., & Xu, G. (2022) · Vaccines · doi:10.3390/vaccines10050742 · Cited by 21
“Common short-term adverse events include local injection site reactions, fever, fatigue, generalized pain, and headache [6,10].”
BackgroundMauro, D., Ciancio, A., Vico, C. D., Passariello, L., Rozza, G., Pasquale, M. D., Pantano, I., Cannistrà, C., Bucci, L., Scriffignano, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901055 · Cited by 25
“Randomized clinical trials and real-life data demonstrated the safety and efficacy of the currently available mRNA vaccine leading to approval nearly worldwide (14, 15).”
BackgroundLiu, S., Zhong, J., & Zhang, D. (2022) · Vaccines · doi:10.3390/vaccines10071083 · Cited by 21
“[3] found that although vaccine efficacy decreases over time, vaccination is still safe and plays an essential role in the prevention of COVID-19.”
BackgroundProcess-biomimetic macromolecular materials for in vivo applications
Gong, X.-F., Li, Y., Wang, D., Cao, H., Yang, Z., Wang, H., & Wang, L. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.101015 · Cited by 22
Islam, M. R., Nasreen, W., Anjum, R., Shahriar, M., Roy, A., Dhama, K., & Bhuiyan, M. A. (2022) · Clinical Pathology · doi:10.1177/2632010x221124908 · Cited by 22
Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review
Tofarides, A. G., Christaki, E., Milionis, H. J., & Nikolopoulos, G. K. (2022) · Life · doi:10.3390/life12122057 · Cited by 23
Marks, K., & Gulick, R. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202310170 · Cited by 23
van den Ouweland, F., Charpentier, N., Türeci, Ö., Rizzi, R., Mensa, F., Lindemann, C., & Pather, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2315659 · Cited by 27
Self-citationDarling, T. L., Harastani, H., Joshi, A., Bricker, T. L., Soudani, N., Seehra, K., Hassan, A. O., Diamond, M., & Boon, A. C. M. (2024) · Science Advances · doi:10.1126/sciadv.adp1290 · Cited by 25
Current Advances in Viral Nanoparticles for Biomedicine
Sun, X., Tian, T., Lian, Y., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c13146 · Cited by 21
Tamming, L. A., Duque, D., Tran, A., Zhang, W., Pfeifle, A., Laryea, E., Wu, J., Raman, S. N. T., Gravel, C., Russell, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785349 · Cited by 22
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Zoli, A., Leoni, O., Borriello, C., Valle, G. P. D., Tirani, M., Pavesi, G., et al. (2022) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(21)00813-6 · Cited by 17
mRNA COVID‐19 vaccine and oral lichen planus: A case report
Caggiano, M., Amato, M., Spirito, F. D., Galdi, M., & Sisalli, L. (2022) · Oral Diseases · doi:10.1111/odi.14184 · Cited by 23
“7% of cases; mild to moderate pain at the injection site was the most frequently self-reported local reaction, while fever and fatigue were the main systemic ones (Thomas et al., 2021).”
BackgroundInfluentialPeng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21
Accelerating discoveries in cancer nanomedicine using AI
Guan, C., Mendes, B. B., Conniot, J., Dias, A. L., Hammad, L., Thambi, T., Langer, R., Rodrigues, T., Conde, J., & de la Fuente‐Núñez, C. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100279 · Cited by 20
Terpos, E., Karalis, V., Ntanasis‐Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20
Zhang, R., Liu, D., Leung, K., Fan, Y., Lu, L., Chan, P.-C., To, K. K., Chen, H., Yuen, K., Chan, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10010072 · Cited by 23
“Some studies also reported a reduction in the effectiveness of COVID-19 at 6 months [7,8].”
BackgroundBechman, K., Cook, E., Dand, N., Yiu, Z. Z. N., Tsakok, T., Meynell, F., Coker, B., Vincent, A., Bachelez, H., Barbosa, I. A., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21042 · Cited by 20
Coria, L. M., Saposnik, L. M., Castro, C. P., Castro, E. F., Bruno, L. A., Stone, W. B., Pérez, P. S., Darriba, M. L., Chemes, L. B., Alcaín, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844837 · Cited by 21
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J. C., Ferrari, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100458 · Cited by 20
“2%] with a 6-month follow-up.(3) Patients with cancer have an increased risk of infection and COVID-19-related morbidity and mortality compared”
Waxman, J. G., Makov-Assif, M., Reis, B. Y., Netzer, D., Balicer, R. D., Dagan, N., & Barda, N. (2022) · Nature Communications · doi:10.1038/s41467-022-29858-5 · Cited by 22
Matveeva, O. V., & Ershov, A. (2022) · Vaccines · doi:10.3390/vaccines10070984 · Cited by 21
The current status of COVID-19 vaccines. A scoping review
Rueda-Fernández, M., Melguizo‐Rodríguez, L., Costela-Ruiz, V. J., González‐Acedo, A., Ramos‐Torrecillas, J., & Montes, R. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.08.004 · Cited by 21
Tu, W., Zhang, P., Roberts, A., Allen, K. S., Williams, J. L., Embí, P. J., & Grannis, S. J. (2022) · American Journal of Public Health · doi:10.2105/ajph.2022.307112 · Cited by 23
Xiangxun, C., Wu, Y., Dau, V. T., Nguyen, N., & Ta, H. T. (2023) · Biomaterials Science · doi:10.1039/d2bm01594c · Cited by 21
Briciu, V. T., Topan, A. V., Calin, M., Dobrota, R., Leucuta, D., & Lupșe, M. S. (2023) · Healthcare · doi:10.3390/healthcare11030373 · Cited by 20
Yu, X., Xu, T., Shi, H., Hong, J., Jin, X., Cao, L., Wang, J., Lin, Y., Pan, Z., Wang, S., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142841 · Cited by 20
SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease
Luxenburger, H., & Thimme, R. (2023) · Gut · doi:10.1136/gutjnl-2023-329623 · Cited by 20
Peptide delivery of a multivalent mRNA SARS-CoV-2 vaccine
McCrudden, C. M., Bennie, L. A., Chambers, P., Wilson, J., Kerr, M. L., Ziminska, M., Douglas, H., Kuhn, S., Carroll, E., O'Brien, G. J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.053 · Cited by 23
Tulling, A. J., Lugthart, G., Mooij, M. G., Brackel, C. L. H., Terheggen‐Lagro, S. W. J., Oostenbrink, R., Buysse, C., Hashimoto, S., van der Aa, L. B., van Aerde, K., et al. (2023) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004098 · Cited by 20
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Usdan, L. S., Patel, S., Rodriguez, H., Xu, X., Lee, D.-Y., Finn, D., Wyper, H., Lowry, F. S., Mensa, F., Lu, C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad718 · Cited by 20
“BA.1-adapted vaccines, the latter of which was authorized in some jurisdictions [3, 15, 26, 28, 32].”
BackgroundSelf-citationNealon, J., Mefsin, Y. M., McMenamin, M. E., Ainslie, K. E. C., & Cowling, B. J. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100451 · Cited by 21
“Gradual reductions in protection, particularly against milder disease, were observed approximately 5 – 6 months after the end of the primary series [5,6].”
BackgroundEstimating Vaccine Efficacy Against Transmission via Effect on Viral Load
Kennedy‐Shaffer, L., Kahn, R. J., & Lipsitch, M. (2021) · Epidemiology · doi:10.1097/ede.0000000000001415 · Cited by 22
Covid-19 vaccines, immunity, and boosters
Richterman, A. G., Scott, J. A., & Çevik, M. (2021) · BMJ · doi:10.1136/bmj.n3105 · Cited by 20
Khan, M. R., Ferdaus, J., Akter, K., Ahmed, H., Parvin, M., Kashif, S., & Arbab, A. S. (2025) · Biomedical Technology · doi:10.1016/j.bmt.2025.100085 · Cited by 20
Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Sakai, H., Hojo, W., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10020158 · Cited by 19
“A pivotal study showed that Asian people tended to have lower vaccine efficacy than other ethnicities, albeit the difference is not significant [10].”
BackgroundTsai, T.-I., Khalili, J. S., Gilchrist, M., Waight, A. B., Cohen, D., Shi, Z., Zhang, Y., Ding, M., Zhu, H., Mak, A. N.-S., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105271 · Cited by 19
Reeg, D. B., Hofmann, M., Neumann‐Haefelin, C., Thimme, R., & Luxenburger, H. (2023) · Pathogens · doi:10.3390/pathogens12020244 · Cited by 23
Guo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 20
“7% from 4 months after the second dose [70].”
BackgroundHickey, T. E., Kemp, T. J., Bullock, J. L., Bouk, A. J., Metz, J. B., Neish, A., Cherry, J. D., Lowy, D. R., & Pinto, L. A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2215677 · Cited by 20
RNA nanotechnology: A new chapter in targeted therapy
Lv, T., Meng, Y., Liu, Y., Han, Y., Xin, H., Peng, X., & Huang, J. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113533 · Cited by 20
Du, H., Saiyed, S., & Gardner, L. (2024) · BMC Public Health · doi:10.1186/s12889-024-17790-w · Cited by 23
Mead, M. N., Seneff, S., Wolfinger, R. D., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024) · Cureus · doi:10.7759/cureus.52876 · Cited by 23
RetractedImpact of vaccination status on clinical outcomes of hospitalized COVID-19 patients
Jelodar, M. G., Mirzaei, S., Saghafi, F., Rafieian, S., Rezaei, S., Saatchi, A., Avare, Z. D., & Niri, M. D. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09139-w · Cited by 14
“Studies indicate that completely vaccinated people, even at a much lower rate than unvaccinated people, still get infected with COVID-19, and no vaccine is 100% effective, but immunization widely decreases hospitalization and death risks [6, 8, 10–16].”
BackgroundRabdano, S. O., Ruzanova, E., Vertyachikh, A. E., Teplykh, V. A., Emelyanova, A. B., Rudakov, G. O., Arakelov, S. A., Pletyukhina, I. V., Saveliev, N. S., Lukovenko, A. A., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106288 · Cited by 22
Wand, O., Nacasch, N., Fadeela, A., Shashar, M., Grupper, A., Benchetrit, S., Erez, D., Shitrit, P., & Cohen‐Hagai, K. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01245-9 · Cited by 19
Gesser‐Edelsburg, A., & Keywan, H. B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.855468 · Cited by 19
Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic
Altoé, A. L., Mambriz, A. P. M., Cardozo, D. M., Zacarias, J. M. V., Visentainer, J. E. L., & Bahls, L. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910138 · Cited by 22
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 20
“Interestingly, that the risk of symptomatic infection after CoronaVac was different based on two studies: 0.15 from Turkey and 0.39 from Indonesia, which can be explained by different extent of severity of the pandemic in these countries.”
BackgroundInfluentialBrunner, W. M., Freilich, D., Victory, J. M., Krupa, N. L., Scribani, M., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.022 · Cited by 21
Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19
“At the 6-month follow-up after two doses, the vaccine showed 91% effectiveness against COVID-19 infection, with the highest efficacy between 7 days and two months after completion of the primary series vaccination, followed by a gradual decline in efficacy, with 84% efficacy at 4 - 6 months [32].”
COVID-19 booster doses in pregnancy and global vaccine equity
Kalafat, E., Magee, L. A., von Dadelszen, P., Heath, P. T., & Khalil, A. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00166-0 · Cited by 20
Nazaruk, P., Monticolo, M., Jędrzejczak, A. M., Krata, N., Moszczuk, B., Sańko-Resmer, J., Pilecki, T., Urbanowicz, A., Florczak, M., Pączek, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9121454 · Cited by 18
“SARS-CoV-2 vaccinations commenced in January 2021; therefore, we currently have a maximum of 6-month vaccine efficacy data available [36].”
BackgroundRamos, A., Cardoso, M. J., Ribeiro, L., & Guimarães, J. T. (2022) · Diagnostics · doi:10.3390/diagnostics12010205 · Cited by 20
Kelliher, M. T., Levy, J., Nerenz, R. D., Poore, B. A., Johnston, A. A., Rogers, A. R., Stella, M. E. O., Snow, S. E., Cervinski, M. A., & Hubbard, J. A. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0607-sa · Cited by 18
Sung, J. C.-C., Lai, N. C.-Y., Wu, K.-C., Choi, M.-C., Ho-Yi, C., Lin, J., Kuok, C.-N., Leong, W.-L., Lam, W.-K., Hamied, Y. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10071014 · Cited by 18
“Many researchers suggested vaccine efficacy declined 6 months after the second dose of injection, especially towards new variants, indicating a booster dose may be required every year [18,19].”
BackgroundPersistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
Alharbi, N. K., Al‐Tawfiq, J. A., Alwehaibe, A., Alenazi, M. W., Almasoud, A. S., Algaissi, A. A., Alhumaydhi, F. A., Hashem, A. M., Bosaeed, M., & Alsagaby, S. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s362848 · Cited by 20
“This indicates a weaning immunity(20) and potentially increases the risk of breakthrough infections overtime.(29) Reduction in antibody titers was reported to occur by 50% every 108 days post-vaccination,(30) with weaning of anti-RBD antibody titer over time starting from day 45 post-vaccination.”
BackgroundAlenezi, S., Alarabi, M., Al-Eyadhy, A. A., Aljamaan, F., Elbarazi, I., Saddik, B. A., Alhasan, K. A., Assiri, R., Bassrawi, R. K., Alshahrani, F. S., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.944165 · Cited by 19
The heterogeneous mixing model of COVID-19 with interventions
Duan, M., & Jin, Z. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111258 · Cited by 15
Technologies Enabling Single-Molecule Super-Resolution Imaging of mRNA
Tingey, M., Schnell, S. J., Yu, W., Saredy, J., Junod, S. L., Patel, D., Alkurdi, A., & Yang, W. (2022) · Cells · doi:10.3390/cells11193079 · Cited by 21
“RNA vaccines against SARS-CoV-2 have exhibited high prophylactic efficiency against the disease during the two years since their development [12,13].”
BackgroundA Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18
“Following a longer period of time, vaccine effectiveness stayed high but somewhat fell to 90% at 2 to 4 months and 84% at 4 to 6 months [27].”
BackgroundBai, J., Chiba, A., Murayama, G., Kuga, T., Yahagi, Y., Tabe, Y., Tamura, N., & Miyake, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24938-4 · Cited by 18
Vaccine hesitancy promotes emergence of new SARS-CoV-2 variants
Jing, S., Milne, R., Wang, H., & Xue, L. (2023) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2023.111522 · Cited by 20
Mayer-Blackwell, K., Ryu, H., Codd, A. S., Parks, K. R., MacMillan, H. R., Cohen, K. W., Stewart, T. L., Seese, A. M., Lemos, M. P., Rosa, S. C. D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101149 · Cited by 21
COVID-19: from immune response to clinical intervention
Guo, Z.-Y., Tang, Y., Zhang, Z.-B., Liu, J., Zhuang, Y., & Li, T. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae015 · Cited by 20
Peluso, M. J., Donatelli, J. L., & Henrich, T. J. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.006 · Cited by 20
“Despite waning antibody titers and increased cases of mild infection, vaccines continue to protect against severe disease and hospitalization for up to 6 months.(51-55) As of now, vaccines remain active against the predominant circulating strains of SARS-CoV-2, and variants that may be more resistant to vaccination, s…”
BackgroundDeterminants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes
Deb, P., Furceri, D., Jiménez, D., Kothari, S., Ostry, J. D., & Tawk, N. (2022) · Applied Health Economics and Health Policy · doi:10.1007/s40258-022-00757-6 · Cited by 20
Falahi, S., Mohamadi, J., Sayyadi, H., Pakzad, I., Rashidi, A., Naserifar, R., Abdi, J., & Kenarkoohi, A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220419133849 · Cited by 18
Drug delivery systems based on renewable polymers: A conceptual short review
Yazdi, M. K., Jabbour, K., Sajadi, S. M., & Esmaeili, A. (2022) · Polymers from Renewable Resources · doi:10.1177/20412479221107469 · Cited by 20
Morrocchi, E., Pighi, C., Pascucci, G. R., Cotugno, N., Medri, C., Amodio, D., Colagrossi, L., Ruggiero, A., Manno, E. C., Tumeo, C. C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac408 · Cited by 19
“Although few data are thus far available on vaccine-induced cellular responses as well as on maintenance over time of SARSCoV-2–specific humoral responses in HIV+ patients, conversely to HCs [17], an early boosting has been suggested in many countries.”
Cengiz, B., Sayılır, M. Ü., Zengin, N. Y., Küçük, Ö. N., & Soylu, A. R. (2022) · Vaccines · doi:10.3390/vaccines10111933 · Cited by 19
Xu, Y., Li, H., Kirui, B. K., Santosa, A., Gisslén, M., Leach, S., Wettermark, B., Vanfleteren, L. E. G. W., & Nyberg, F. (2022) · Vaccines · doi:10.3390/vaccines10122074 · Cited by 19
Lanman, T. A., Wu, C., Cheung, H., Goyal, N., & Greene, M. (2022) · The Neurohospitalist · doi:10.1177/19418744211065242 · Cited by 18
Benning, L., Morath, C. P., Bartenschlager, M., Reineke, M., Töllner, M., Nußhag, C., Kälble, F., Reichel, P., Schaier, M., Klein, K., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.01.011 · Cited by 19
“Recently, follow-up data from the phase 2e3 BNT trial reported a gradual decline in vaccine efficacy from 96% between 7 days and 2 months after the second dose to 84% between 4 and 6months after the second dose [4].”
Evidence linking COVID-19 and the health/well-being of children and adolescents: an umbrella review
Duan, C., Liu, L., Wang, T., Wang, G., Jiang, Z., Li, H., Zhang, G., Li, Y., Li, C., & Cao, Y. (2024) · BMC Medicine · doi:10.1186/s12916-024-03334-x · Cited by 18
“Nonetheless, this does not suggest evidence against the vaccine’s safety, as reactogenicity is more common in young individuals than in adults [199].”
BackgroundBullock, J. L., Hickey, T. E., Kemp, T. J., Metz, J. B., Loftus, S. A., Haynesworth, K., Castro, N. D., Luke, B. T., Lowy, D. R., & Pinto, L. A. (2024) · Vaccines · doi:10.3390/vaccines12050516 · Cited by 17
“Both vaccines showed excellent efficacy via the elicitation of neutralizing antibodies to the original virus strain up to 6 months after vaccination [7,8]; however, many studies have confirmed low antibody titers at later timepoints [9–13].”
BackgroundSimulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan
Furuse, Y. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05025 · Cited by 17
Tao, S., Bragazzi, N. L., Wu, J., Garcia, B. R. M., & Kong, J. D. (2022) · Scientific Reports · doi:10.1038/s41598-021-04731-5 · Cited by 17
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
Hatzakis, A. E., Karabinis, A., Roussos, S., Pantazis, N., Degiannis, D., Chaidaroglou, A. S., Petsios, K. T., Pavlopoulou, I. D., Tsiodras, S., Paraskevis, D. N., et al. (2022) · Vaccines · doi:10.3390/vaccines10020285 · Cited by 18
“7% for BNT162b2, while no change was noted for mRNA-1273 [4,5].”
BackgroundGranata, V., Fusco, R., Villanacci, A., Magliocchetti, S., Urraro, F., Tetaj, N., Marchioni, L., Albarello, F., Campioni, P., Cristofaro, M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060955 · Cited by 18
Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 18
Harboe, Z. B., Hamm, S. R., Pérez‐Alós, L., Sivapalan, P., Priemé, H., Wilcke, T., Kjeldgaard, P., Shaker, S. B., Jordan, A. S., Møller, D. L., et al. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001268 · Cited by 20
Abuhammad, S., Khabour, O. F., Alzoubi, K. H., Hamaideh, S. H., Alzoubi, B. A., Telfah, W. S., & El-zubi, F. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271625 · Cited by 18
Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives
Lagousi, T., Gkentzi, D., Geropeppa, M., Tsagkli, P., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10111953 · Cited by 19
Aldali, J. A., Meo, S. A., & Al-khlaiwi, T. (2023) · Vaccines · doi:10.3390/vaccines11020231 · Cited by 19
“[29] conducted a study on the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine and found that BNT162b2 had a favorable safety profile and was highly efficacious in preventing COVID-19.”
BackgroundPradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar‐Gurrieri, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106457 · Cited by 17
Cuypers, L., Keyaerts, E., Hong, S., Gorissen, S., Menezes, S., Starick, M., Elslande, J. V., Weemaes, M., Wawina-Bokalanga, T., Martí-Carreras, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00421-1 · Cited by 6
Roadmap to next-generation cancer vaccines
Zheng, Y., & Zhong, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.005 · Cited by 17
COVID-19 Vaccine Breakthrough Infections in Veterans Health AdministrationPreprint
Sharma, A., Oda, G., & Holodniy, M. (2021) · medRxiv · doi:10.1101/2021.09.23.21263864 · Cited by 20
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
Zou, H., Yang, Y., Dai, H., Xiong, Y., Wang, J., Lin, L., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732403 · Cited by 16
Probable Vogt–Koyanagi–Harada Disease after COVID-19 Vaccination: Case Report and Literature Review
Ding, X., & Chang, Q. (2022) · Vaccines · doi:10.3390/vaccines10050783 · Cited by 16
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.